HKEX: 9606
2026 Interim report
Earlier from Duality Biotherapeutics
- DualityBio Announces China NMPA Acceptance of Biologics License Application Seeking Approval for Trastuzumab Pamirtecan for the Treatment of Unresectable or Metastatic HER2-Positive Adult Breast Cancer
- DualityBio (9606.HK) Announces 2025 Annual Results
- DualityBio's Next-Generation HER3 ADC DB-1310 Granted FDA Fast Track Designation
- First Patient Dosed in Phase 1/2 Clinical Study of Novel EGFR/HER3 Bispecific Antibody-Drug Conjugate AVZO-1418/DB-1418